Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic- related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer a...

OBJECTIVES To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach. METHODS Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and safety of oral ospemifene 60 mg/day for the treatment of sy...

Seventy-four postmenopausal women presenting with vaginal atrophy were treated with either Ovestin vaginal cream (Group A, 23 women: 1 mg/day E3; Group B, 30 women: 0.5 mg/day E3) or vaginal suppositories (Group C, 21 women: 0.5 mg/day E3), applied daily for 3 wk (A and B) or 2 wk (C) before retiring. Ten women from A and 10 from B applied a maintenance dose (1 application twice weekly) during ...

In a 3-year prospective study, 30 postmenopausal women received transdermal E2 gel and every-other-day vaginal P in capsules. At study completion, endometrial thickness was significantly reduced as compared with baseline (2.7 0.5 vs. 3.4 0.9 mm), endometrial biopsy showed endometrial atrophy in all cases, and amenorrhea was achieved in 92.6% of cycles, while excellent patient satisfaction was a...

The prevalence of vaginal atrophy is particularly high among women who have undergone treatment for gynecological cancers, since they significantly lower estrogen levels and altered microbiota. These patients often experience discomfort, dryness, pain, but rarely report this to a doctor. Such symptoms affect patients’ quality life might cause family breakdown. This article proposes safe therape...

purpose : to investigate and compare the causes of blindness in ocular behçet’s disease (bd) in men and women methods : in a retrospective, descriptive investigation from 1976 to 2008, 6,021 bd cases were registered in our bd unit of shariati hospital of tehran university of medical sciences (tums). at the last visit, 187 patients (124 men and 63 women) were blind (vision=1/10 or less) at least...

conclusions multiple associations existed between atrophic urogenital changes and urinary incontinence. the most significant interaction was between urinary tract infections and urinary incontinence in menopausal women, with urinary tract infections increasing the risk of incontinence by 5.6 fold. we recommend health professionals to focus on early screening of these issues and implement educat...

OBJECTIVE To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1. METHODS This prospective, randomized, double-blind and placebo-controlled phase III clinical trial studied the effect of prasterone (DHEA) applied locally in the ...